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Abstract
Background: Psittacosis outbreak investigations require rapid identification of cases in order to trace possible
sources and perform public health risk assessments. In recent outbreaks in the Netherlands, such investigations
were hampered by the non-specificity of laboratory testing methods to identify human Chlamydia psittaci
infections.
Method: A systematic search of PubMed and Scopus databases of literature published between 01 January, 1986
and 03 July, 2017 was done to find best practices of laboratory-testing methods used in psittacosis outbreaks of
two or more human cases. Reference lists of included articles were hand searched to identify additional articles.
Results: Thirty-seven eligible articles were identified, describing 44 human psittacosis outbreaks in 12 countries.
Laboratory tests performed were PCR (with various targets), serologic tests (complement binding reactions, ELISA’s,
immunofluorescence tests and immuno-peroxidase tests) and culture, in various combinations. The literature provided
no ‘gold standard’ laboratory testing strategy to identify recent human C. psittaci infections. In most psittacosis outbreaks,
for a considerable number of cases (or tested individuals in an exposed cohort), C. psittaci infection could not
be confirmed, nor excluded as causative pathogen. None of the testing strategies was found to be suitable
for (nearly) full case finding.
Conclusion: PCR enables rapid identification of human psittacosis patients and helps source finding by genotyping
but has the disadvantage that sensitivity is high only in the acute phase. In outbreak situations, there is often a time
delay and therefore, there is a need for new serologic testing methods next to PCR, with good specificity and sensitivity.
Moreover, serum is easier to collect than the preferred diagnostic materials for PCR. A serologic test that can
reliably confirm infection status without the necessity of convalescent serum sampling would enhance case
finding, source tracing, identification of risk factors and assessment of burden of disease in various settings.
Keywords: Psittacosis, Chlamydia psittaci, Diagnostics, Disease outbreaks, Epidemiology, Systematic review,
Zoonoses.
Background
Psittacosis is a zoonotic disease, which regularly causes
small outbreaks worldwide. Traditionally, psittacines
(parrot-type birds) have been considered as reservoir of
the causative bacterium, Chlamydia psittaci. In addition,
many other birds, including wild birds and commercially
kept poultry, have also been implicated [1].
In the Netherlands, an outbreak occurred in 2007
among visitors to a bird show [2, 3]. After confirmation of
the diagnosis by real-time polymerase chain reaction
(PCR) of three hospitalized patients, a retrospective cohort
study among about 200 visitors was started. Serological
screening and a questionnaire study were performed in
order to estimate attack rates and identify risk factors.
Based on screening immunoglobulins (Ig)(IgG/A/M) with
a genus specific enzyme-linked immunosorbent assay
(Chlamydia r-ELISA, Medac Diagnostika) and a comple-
ment fixation test (CFT) on sera taken 23 days after the
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bird show, the attack rate was very high (42/156, 27%),
but surprisingly none of the IgM concentrations of sus-
pected infected visitors showed a significant rise after a
mean of 14 days to confirm a recent infection. To verify
the unexpected high attack rate, a set of control sera of 30
healthy volunteers was also tested with the same ELISA.
Thirty percent of the single control sera showed an IgM
response. None of these serological responses could be ex-
plained by zoonotic bird contact. It was unclear if this high
seroprevalence was due to cross-reaction with other
Chlamydia species, especially with Chlamydia pneumoniae
or false positivity of the ELISA test [2, 4, 5]. The lack of a
C. psittaci-specific antibody test therefore hampered a
proper serological interpretation of the epidemiological out-
break investigation.
In 2012, similar problems occurred with investigation of
another outbreak in the Netherlands with eight confirmed
cases among visitors and volunteers working for a bird
sanctuary. Three persons were hospitalized and diagnosed
with pneumonia (including the index case). For the epide-
miologic investigation of this outbreak, a cohort of more
than a 100 volunteers as well as 3 payed workers was re-
quested to fill in a questionnaire about demographics,
symptoms, medical care sought, medication use, medical
history and possible exposures. Out of 40 respondents who
reported symptoms, 25 met the formulated clinical case
definition for psittacosis of this outbreak. Convalescent
serological samples of 19 cases were taken three times
within a 3–4 week interval. Serology was performed on
these samples for the identification of antibodies against C.
psittaci (micro-immunofluorescence tests (MIF) IgG for C.
psittaci) and to exclude other Chlamydia species (MIF IgG
for C. pneumoniae, ELISA IgM/A/G for C. pneumoniae
and MIF IgG for C. trachomatis). Six patients tested posi-
tive for C. psittaci with a fourfold rise in IgG titer. PCR for
C. psittaci was used in 12 patients, of whom two tested
positive. Nasal-pharyngeal swabs for PCR testing were
taken three to 14 days after onset of symptoms with ex-
ception of a sputum sample of an intensive care (ICU) pa-
tient, which was taken after 22 days. PCR to exclude C.
pneumoniae, Coxiella burnetii, and influenza virus A was
performed in nine patients, who all tested negative for
these pathogens [6](personal communication N. Reedijk
17–08-2016 and 21–03-2017).
This meant that despite the use of a combination of la-
boratory tests, C. psittaci could be confirmed in a small
number of the suspected cases only. For majority of the
cases tested, it remained unclear whether infection with C.
psittaci was the cause of their symptoms. Therefore, in spite
of the availability of extensive information from the ques-
tionnaire, formal epidemiological analysis lacked possibil-
ities and was unsatisfactory. The difficulties with the
laboratory diagnostics in this outbreak were amongst others
related to omitting laboratory diagnostics for C. psittaci by
physicians (patients are treated empirically), non-optimal
sampling intervals (caused by medical consultation delay
and sampling delay) and lack of suitable clinical material
for PCR testing (no sputum or broncho-alveolar lavage
(BAL) available for non-hospitalized patients) [4, 6], (per-
sonal communication N. Reedijk 17–08-2016).
Both outbreaks in the Netherlands showed the con-
straints in confirming human psittacosis cases with
PCR-based diagnostics because of time delay, decline of
sensitivity of PCR in time and/or unavailability of appropri-
ate diagnostic material. Serology with convalescent sam-
pling is the alternative to screen possible exposed persons.
The difficulties in interpreting laboratory findings in
these outbreak settings prompted us to do a systematic
review of the international literature on psittacosis out-
breaks with special emphasis on the laboratory methods
used, in order to find out which (combination of ) la-
boratory testing methods could be advised for psittacosis
outbreak investigations.
Methods
Search strategy
The search strategy we developed aimed to find descrip-
tions of human psittacosis outbreaks with a special focus
on diagnostic laboratory methods. We searched PubMed
and Scopus for items published between 1 January 1986 and
3 July 2017, using MESH (Medical Subject Headings)and
keywords psittacosis, Chlamydia or Chlamydophila psittaci,
psittaci, outbreak*, disease outbreaks, epidemiology, epi-
demic, human(s) and not animals. The complete search
strategies are given in Additional file 1. All results were com-
bined in one EndNote X8 file (Clarivate Analytics USA) and
duplicates removed using EndNote and by hand. There was
no language restriction in our search but we could
only read full texts of selected articles in Dutch, Eng-
lish, German, French and Spanish. At a later stage,
reference lists of selected full texts were checked to
identify studies possibly missed by our search strategy.
Finally, the Cochrane library was checked for system-
atic reviews that included information on the topic of
our review with the keyword ‘psittacosis’ and key-
words ‘Chlamydia psittaci’, without relevant results.
In- and exclusion criteria
Two authors (AN, FD) used a pilot search of PubMed
with keywords ‘psittacosis outbreak’ to specify in- and
exclusion criteria before the title and abstract screening.
Figure 1 shows the definitive in- and exclusion criteria.
In summary, articles describing an outbreak of human
psittacosis with at least two possible human cases and
with specification of the laboratory test methods used to
confirm infection were included. Articles with description
of psittacosis outbreaks among humans that took place
before 1986 were excluded, because before that time, C.
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pneumoniae was designated as C. psittaci strain TWAR
(Taiwan acute respiratory agent) [7, 8] and could not be
differentiated from C. psittaci [9, 10]. We also excluded
single case reports and reviews or other publications not
based on original data. We did not find any human out-
breaks when articles mentioned C. psittaci as cause of
abortion, ocular lymphoma or trachoma in the pilot
search. Articles with these topics were therefore other rea-
sons for exclusion. Full text articles, in which the type of
laboratory tests that were used were not specified, were
also excluded.
Title and abstract screening
In the first screening stage, the in- and exclusion criteria
were applied to the titles and abstracts resulting from the
literature search. This title and abstract screening was
done independently by two investigators (AN, FD) for the
PubMed and Scopus search results. PubMed and Scopus
items were excluded when both authors considered them
not relevant. An item was selected from PubMed or Sco-
pus search for full text screening if at least one of the au-
thors (AN, FD, WvdH) labeled it as possibly meeting the
inclusion criteria. Articles without abstract were included
Fig. 1 PRISMA flow diagram of the systematic search and selection results
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for full text screening when the title seemed relevant.
When at least one of the authors (AN/FD, AN/WvdH)
had doubt about exclusion after the initial selection round
of PubMed or Scopus database items for full text screen-
ing eligibility, a third author was consulted and disagree-
ments solved by discussion.
Full text screening
In the second screening stage, the in- and exclusion cri-
teria were applied to the full text articles that resulted
from the title and abstract screening. Three authors
(AN, FD, WvdH) did this independently. Disagreements
about selecting an item were resolved by discussion be-
tween the authors (AN, FD, WvdH). This yielded the full
text articles that were included in the review.
Reference lists of the selected full text were checked
by hand to find extra titles that were missed by the
search. These extra titles were screened for inclusion by
the same method as the PubMed and Scopus titles.
Data extraction
We extracted the following data from the included arti-
cles: year and country of the outbreak, population and
setting, the laboratory test(s) performed to diagnose C.
psittaci infection in humans, number of patients tested
as well as number of patients positive by the laboratory
test. Data extraction was done by AN. Uncertainties
were resolved by discussion between the authors (AN,
FD, WvdH).
Results
Characteristics of articles included for review
Our search strategy resulted in 739 titles of which 34 ar-
ticles met our criteria for full text inclusion for review
(see Fig. 1). The PubMed (373) and Scopus (366) data-
base provided 34 of these articles. In addition, three
more articles were found by checking the reference lists
of the included full texts. The selected 37 eligible articles
described 44 outbreaks of human psittacosis in twelve
different countries over the period 1986 through 2014
(Table 1). Seven of the 16 larger outbreaks with ten or
more cases, took place in poultry processing plants/
slaughterhouses and poultry farms [11–17]. Other larger
outbreaks were related to a bird show or bird park [3,
18, 19], at a veterinary teaching hospital [20], an aviary
in an institution [21], a distribution of birds from the
same breeder [22] and two were linked to wild birds in
Australia [23, 24]. In one large outbreak transmission
took place in hospital setting [25]. More than half of the
articles (21/37, 57%) described one or more smaller out-
breaks with two to nine people tested with laboratory
methods. Eight [26–33] of these smaller outbreaks oc-
curred at family homes and were linked to pet birds, six
took place at poultry farms or poultry processing plants
[31, 34–38], three were linked to a (pet or other) shop
[39–41], two described outbreaks at hospitals, with hu-
man psittacosis patients as source [42, 43], two con-
cerned workers and students at a veterinary clinic or
school [44, 45] and one was linked to a parrot relief and
breeding center [46].
Psittacine birds were mentioned as possible sources in
43% (16/37) of the articles. Fifty-four percent (20/37)
was linked to other birds of which 65% (13/20) to
poultry. The articles of outbreaks at farms, breeders or
processing plants all mentioned poultry, including
chicken, ducks, geese, turkeys and peacocks, as possible
source. In 16% (6/37) of the included articles direct or
indirect contact with wild birds (for example: psittacines,
pigeons, gulls, wild bird feathers or excrements), were
considered possible sources [16, 23–25, 43, 44]. Expos-
ure to an equine fetal membrane caused a small out-
break at a veterinary school and equine stud farm [45].
Some outbreaks occurred after hospitalization of a
bird-infected index case, which spread the infection
person-to-person amongst their contacts [25, 43].
Laboratory tests used
In the included psittacosis outbreaks, culture, serology
and PCR were the types of laboratory procedures that
were performed to diagnose psittacosis or to exclude path-
ogens other than C. psittaci (e.g. Legionella, Mycoplasma)
or cross reactivity (e.g., C. pneumoniae, C. trachomatis)
(Table 1). Most articles describe combinations of these
tests but in seven articles, all published before 1998, only
one test was used to diagnose C. psittaci infection.
Serology
In all of the included articles, at least one serological test
was used. These were complement fixation tests (CFT),
enzyme(−linked) immunosorbent assay tests (ELISA/EIA
including recombinant ELISA), (micro-)immunofluores-
cence tests and whole cell immunofluorescence tests
(IF/MIF/WHIF) and immuno-peroxidase tests (IPA). IF/
MIF (including IPA [15, 31, 32] and WHIF [34]) was
used in the majority of the articles (27/37, 73%),
followed by CFT (20/37, 54%) and EIA/ELISA testing
(5/37, 14%). CFT and IF were used regularly in outbreak
investigations from 1985 up to 2014 in contrast to
ELISA/EIA. Only in the period 2003–2007 [16, 20, 36,
46] and thereafter in 2014 [45] ELISA/EIA testing was
found in our review.
In many articles problems occurred with the (un-)-
availability of convalescent serum samples needed for
confirmation of cases or the second sample did not
show seroconversion, which makes interpretation and
conclusions difficult. Clinical symptoms, in combin-
ation with suspected test results, made assumption of
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a positive psittacosis infection case more acceptable
for positive interpretation.
PCR
PCR for laboratory diagnosis of C. psittaci was reported in
16 articles (16/37, 43%). In 2006, Heddema et al. were the
first to describe PCR to identify C. psittaci in humans in an
outbreak situation in 2004, although Williams et al. (1998)
performed PCR on human lung tissue postmortem of one
single case in 1995 [20, 23]. Telfer et al. (2005) used a C.
pneumoniae-specific PCR on hospitalized case-patients to
exclude C. pneumoniae in an outbreak in Australia in 2002
[24]. From 2006, PCR techniques to identify C. psittaci in
human patients were reported in 15 of 19 (79%) of the in-
cluded articles. PCR was used only in addition to a sero-
logic testing method, while culture was used next to PCR
in seven of the 15 PCR articles (47%). PCR was mainly per-
formed on hospitalized patient samples. Among the arti-
cles, the PCR testing methods described differed in DNA
targets, in species and genus specificity, and in amplifica-
tion and detection techniques. In addition, there was vari-
ation in the sampled clinical material used for PCR
testing. We found BAL, sputum, throat swabs, nasal and
pharyngeal swabs, blood and urine as test material taken
for PCR. BAL and sputum are considered the best mater-
ial for performing C. psittaci PCR, but this was often not
available. Easier to collect are nasal, pharyngeal and throat
swabs, blood and urine. Verminnen et al. (2008) reported
pharyngeal and nasal swabs to be more suitable than spu-
tum but this could be due to problems to produce sputum
in many patients [36]. Only in two studies more than 10
people were tested with PCR. Fifty percent (4/8) of the
sputum samples and 14% (5/37) of the throat swabs tested
PCR positive in these larger studies [3, 20]. For the other
outbreaks, the numbers of cases tested with PCR were
small. Throat swabs scored less frequently positive (17%, 8/
48) compared to nasal and pharyngeal swabs, BAL and spu-
tum. Nasal swabs scored best of the swabs (100%, n = 5)
comparable with BAL (100%, n = 6) followed by sputum
(71%, 12/17) and pharyngeal swabs (70%, 7/10). Urine was
used for PCR in three outbreaks [3, 17, 44]. Gaede et al.
(2008) reported C. psittaci genotype A detection in urine of
a BAL positive patient [17]. Williams et al. (2013) used dir-
ect immunofluorescence test (DIF) on sputum samples and
performed DNA micro-array based genotyping on one DIF
positive sample [34].
Figure 2 shows an overview of serology tests and PCR
used in the psittacosis outbreaks of selected outbreak ar-
ticles over time.
Culture
Culture for C. psittaci was described in 30% (11/37) of
all the articles, always in addition to other tests. Cultur-
ing C. psittaci was used mostly to confirm the outcome
of the serological test(s) and/or PCR in one or a few
index cases. Culturing other agents was done to be able
to exclude these as causative pathogens. Culture was
still used several times after PCR testing became avail-
able (58%, 7/12) (Table 1) although biosafety level three
is needed and C. psittaci culture is not routinely per-
formed in most diagnostic laboratories. BAL or sputum,
pharyngeal aspirates or swabs are considered the best
materials for culturing C. psittaci, and comparable to
best material for PCR tests taken in the acute phase of
infection.
In some articles included in the review that mentioned
culture, it was not clear whether this was specifically for
C. psittaci, or referred to routine (blood, sputum, urine)
culture for other possible pathogens of respiratory infec-
tions. None of the blood cultures identified C. psittaci.
This might indicate blood culture was performed mainly
for other agents. Culturing of sputum (or other respira-
tory material) was more likely to include C. psittaci and
more often reported positive results compared to blood
cultures.
Best practice
We did not find a standard algorithm or uniformity in test-
ing methods. Wide varieties of testing methods and various
sorts of combinations of these have been used. Each of
these testing strategies was intended to deal with the low
specificity and/or sensitivity of some of the individual tests
and the availability of test material at the right moment
during an infection period. A general tactic described in the
articles in this review, both for PCR and for serology, is the
use of a genus specific test as a first step, followed by a
more specific (i.e. species-specific) test to exclude other
chlamydial species, especially C. pneumoniae and C. tracho-
matis. Besides testing strategies to diagnose C. psittaci,
many articles describe additional diagnostic tests to exclude
other pathogens that may cause comparable clinical syn-
dromes, especially influenza like illnesses and community
acquired pneumonia (CAP). These tests may act as a first
step in multi-stage testing. Testing for C. psittaci will be
considered only after exclusion of those other pathogens,
or when e.g. history of bird contact or other circumstances
are suggestive for psittacosis. These first stage tests to ex-
clude other pathogens are beyond the scope of this review.
Comprehensive testing strategies for outbreak situations
were found in the articles of Heddema et al. (2006) [20]
and of Belchior et al. (2011) [19]. In an outbreak at a veter-
inary teaching hospital, Heddema et al. (2006) used PCR
[47] in as many subjects as possible in combination with
serology (CFT and ELISA on paired samples) for human
case finding. In addition, they performed PCR among
potential bird sources for veterinary case finding and
culture to exclude other human respiratory pathogens. In
an outbreak study related to a bird show, Belchior et al.
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(2011) used serology (MIF) in combination with two differ-
ent PCR tests (one targeting a C. psittaci-specific incA gene
[48], and one targeting a Chlamydiaceae-specific 23S rRNA
gene [49]) for human case finding. The latter PCR test was
also used for veterinary source finding and genotypical
matching but matching failed because genotyping of PCR
positive human samples was impossible due to lack of suffi-
cient DNA.
Both Heddema et al. (2006) and Belchior et al. (2011)
were able to confirm C. psittaci as causative agent of the
outbreak and exclude other chlamydial species. However, in
both studies, only a few of the tested human cases could be
confirmed despite early recognition of the outbreak. Most
of the tested cases remained classified as ‘possible C. psittaci’.
Nevertheless, with the testing strategy of Heddema et al.
(2006), the investigators were able to identify the (possible)
source of the outbreak by a genotypic match between a bird
source and human cases.
Discussion
In recent outbreaks in the Netherlands, serological la-
boratory test results to identify acute and non-acute hu-
man C. psittaci infections turned out to be non-specific,
thereby precluding the monitoring of the number of
confirmed cases, detection of possible sources, and iden-
tification of risk factors. The difficulties with laboratory
Fig. 2 History of serology and PCR testing in psittacosis outbreaks 1985–2014. *1993–2000 PCR only on post-mortem material [34]
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testing strategies in outbreak settings prompted us to do
a systematic review of the international literature of la-
boratory methods used in psittacosis outbreaks.
However, the main findings of the review are that a
wide variety of (combinations of ) testing methods are
being used and that no (gold) standard or uniformity in
testing strategies exists. For outbreak investigation, each
single test method has drawbacks, ranging from low sen-
sitivity or cross-reactivity with related species, to issues
relating to the unfeasibility to collect the optimal clinical
material at the optimal time intervals for the respective
tests. It is clear that in a considerable number of cases
(or tested individuals in an exposed cohort) in most psit-
tacosis outbreaks, C. psittaci infection cannot be con-
firmed, nor can C. psittaci be excluded as causative
pathogen. Although studies were found in which the in-
vestigators made considerable efforts to deal with known
limitations of the single test methods, by collecting vari-
ous sorts of clinical materials and using a broad combin-
ation of tests, none of these testing strategies seemed to
be suitable for (nearly) full case finding.
Evaluation of testing strategies
The current existing test methods for C. psittaci can be di-
vided into culture, PCR and various serological methods,
namely CFT, ELISA/EIA, IF and IPA tests. In all out-
breaks, serologic methods were used. However, because of
cross reactivity with other Chlamydial species, serological
testing of a serum sample taken at one single moment will
not be sufficient for confirmation [50]. Therefore, PCR
testing or culture, which have a higher specificity, can
be performed in addition. For these test methods,
clinical material from the lower respiratory tract is
preferred, i.e. sputum or BAL [51]. However, these
materials are frequently not available, especially not
in outpatients, and considered as rather invasive to
obtain. PCR is also being performed on other clinical
material, like throat swabs, but then sensitivity is as-
sumed to be considerably lower although few com-
parative studies have been performed [36, 51, 52].
Furthermore, PCR is only of use early in the infection
and is therefore of limited value for retrospective case
finding or investigating asymptomatic exposure.
To overcome the problems with the low specificity of
single point serology, serological testing on convalescent
sera can be performed, taken with an interval of several
weeks but we found no standard for the optimal time
interval. This approach has two disadvantages. First, sera
from the acute phase of the illness are necessary, which
is only possible if all cases or cohort members are sam-
pled early in the outbreak. Second, samples from a few
weeks later are necessary. This requires a sampling pro-
cedure that might be difficult to implement in practice.
Taking convalescent sera is time consuming, expensive
and is unlikely to be relevant for clinical management of
individual patients, whose symptoms might have already
subsided after presumptive antibiotic therapy. At present
time, ELISA techniques lack specificity and IF tech-
niques are more reliable when they are performed in
3-spot IF, including C. trachomatis, C. pneumoniae and
C. psittaci. Finding a high IgM titer, in combination with
clinical symptoms and/or history of a patient, can pro-
vide an early probable case diagnosis before waiting for
the second serum sample for confirmation.
In outbreaks of psittacosis, there is often a consider-
able time delay between onset of symptoms in patients
and laboratory diagnostic testing. History of bird contact
may be absent. When history is not taken carefully and
bird contact unknown, standard diagnostics in patients
with pneumonia usually do not include tests for C. psit-
taci infection [53]. Therefore, many psittacosis index pa-
tients are discovered late and in hospital situations. Or,
they might not be recognised due to lack of sensitivity of
PCR because test material is taken long after start of in-
fection and/or first serum samples do not show high
antibody titres. Diagnosis confirmation by serology takes
at least two weeks after taking the first sample, and is
therefore always retrospective. Culturing C. psittaci also
takes more time than PCR for specific diagnosis, is not
easy and has the disadvantage that it has to be per-
formed under biosafety level three laboratory conditions.
PCR is on the other hand, a specific and fast method
when performed on suitable acute phase respiratory ma-
terial. If the possibility exists to use a C. psittaci specific
PCR (and not a genus specific PCR), this is the most
specific and fastest method to confirm an individual
suspected psittacosis patient. Nevertheless, the delays
as mentioned above hamper rapid specific diagnosis
of psittacosis especially by PCR when bird contact is
not obvious. Of course, the chosen testing strategy
will depend also on the availability of tests, test
material and their sensitivity and specificity in com-
bination with the likelihood of a psittacosis case or
possible outbreak in mind.
Implications for epidemiological investigation
In any psittacosis outbreak, confirmation of human cases
will take some time, because of the incubation time of
the disease, patient delay in seeking medical care, diag-
nostic delay (i.e. the time from first medical examination
to a possible or confirmed diagnosis), and delay in rec-
ognition that there is a possible outbreak situation, after
the first human and/or veterinary cases have occurred.
In practice, this period might last several weeks. There-
fore, delays in sampling of symptomatic cases and
asymptomatic exposed people cannot be prevented. This
means that full case finding with the current available la-
boratory methods for the diagnosis of C. psittaci, is
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impossible. Rather than trying to test all possible cases,
it seems more efficient to focus on early confirmation
of an outbreak based on PCR testing of only a few
cases, i.e. confirm C. psittaci with laboratory methods
in some epidemiological linked individuals. Genotyp-
ing of PCR-positive samples will facilitate source tra-
cing. In addition, further risk factor analysis can then
be based on a clinical case definition. However, with
many probable and possible cases, based on such a
clinical case definition, it will be difficult to obtain re-
liable estimates of disease burden.
Limitations of the study
Our review is based on three decades of international
literature on laboratory-testing strategies used for the
diagnosis of C. psittaci in human psittacosis outbreaks.
Unfortunately, we had to exclude 18 potential relevant
articles because of the language or because we were not
able to retrieve the full text. However, the English ab-
stracts of these excluded articles, when available, did not
describe deviating methods, settings or populations from
the included literature.
Another difficulty in the selection process of articles
was when more than one case was described and we had
to consider if the setting was an outbreak or not. Some
interesting articles had unusual situation. Vorimore et al.
(2015) described several psittacosis cases but we consid-
ered these more likely to be separate cases gathered over
time than to be part of an outbreak. These cases worked
on different duck farms with laying flocks but had duck
insemination with semen from a single male flock, diag-
nosed as heavy shedders, in common [54]. Branley et al.
(2014) described an endemic situation in Australia of
community-acquired psittacosis in the period 2003–
2009 but not an outbreak. Sixty percent of the cases did
not have history of direct bird contact but indirect con-
tact was universal. Moreover, only a low prevalence of C.
pneumoniae was present [55]. The systematic review is
complicated by the changes in nomenclature over the
years, from Chlamydia to Chlamydophila psittaci and
back, and the discovery of new Chlamydia subtypes. We
excluded newly described non-avian strains, such as C.
abortus, C. caviae, C. felis and C. pecorum, by restricting
our search to C. psittaci outbreaks with a link to birds
only and not to other animals. Outbreaks of human psit-
tacosis without bird contact, i.e. caused by non-avian
strains, have not been reported, although case reports
have been published [56]. Recently, two more Chla-
mydiae species were described to infect birds i.e. C.
avium and C. gallinacea. The zoonotic potential of these
new species is not established well yet, but infection may
not be detected by the currently available PCR tests for
C. psittaci [57, 58]. Laroucau et al. (2015) describe
human psittacosis cases in contact with C. gallinacea
and C. psittaci co-infected poultry but C. gallinacea
could not be identified in the human cases [35].
Another challenge for the present review was that la-
boratory methods and case definitions in the included
articles often were described poorly and differed be-
tween outbreaks. Therefore, it was difficult to categorize
the reported laboratory methods and to assess the num-
ber of cases tested positive.
Conclusion
PCR enables rapid identification of acute symptomatic
and asymptomatic human psittacosis patients and helps
source finding by genotyping in outbreaks. However,
sensitivity of PCR declines rapidly in the time period be-
tween onset of illness and seeking medical care and per-
forming laboratory testing. Moreover, suitable material
to use for PCR testing is not easily available. We con-
clude that there is a need for new serologic testing
methods next to PCR, with good specificity and sensitiv-
ity, preferably in a single sample, for confirmation of
psittacosis cases in outbreaks.
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